Literature DB >> 20567544

New Research in Ulcerative Colitis: Optimizing 5-ASA Administration for Efficacy and Adherence.

Charles A Sninsky1.   

Abstract

Entities:  

Year:  2010        PMID： 20567544      PMCID： PMC2886447     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  28 in total

1.  Comparative, open, randomized trial of the efficacy and tolerance of slow-release 5-ASA suppositories once daily versus conventional 5-ASA suppositories twice daily in the treatment of active cryptogenic proctitis: French Pentasa Study Group.

Authors:  P Marteau; C Florent
Journal:  Am J Gastroenterol       Date:  2000-01       Impact factor: 10.864

Review 2.  Epidemiology and risk factors for colorectal dysplasia and cancer in ulcerative colitis.

Authors:  Edward V Loftus
Journal:  Gastroenterol Clin North Am       Date:  2006-09       Impact factor: 3.806

Review 3.  Intestinal luminal pH in inflammatory bowel disease: possible determinants and implications for therapy with aminosalicylates and other drugs.

Authors:  S G Nugent; D Kumar; D S Rampton; D F Evans
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

4.  Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.

Authors:  Stephen B Hanauer; William J Sandborn; Asher Kornbluth; Seymour Katz; Michael Safdi; Scott Woogen; Gino Regalli; Chyon Yeh; Nancy Smith-Hall; Funmilay Ajayi
Journal:  Am J Gastroenterol       Date:  2005-11       Impact factor: 10.864

5.  Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.

Authors:  Fernando S Velayos; Jonathan P Terdiman; Judith M Walsh
Journal:  Am J Gastroenterol       Date:  2005-06       Impact factor: 10.864

Review 6.  Mesalamine with MMX technology for the treatment of ulcerative colitis.

Authors:  Stefan Schreiber; Michael A Kamm; Gary R Lichtenstein
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2008-06       Impact factor: 3.869

7.  Response and remission are associated with improved quality of life, employment and disability status, hours worked, and productivity of patients with ulcerative colitis.

Authors:  Walter Reinisch; William J Sandborn; Mohan Bala; Songkai Yan; Brian G Feagan; Paul Rutgeerts; Graham Radford-Smith; Stephen Xu; Debra Eisenberg; Allan Olson; Jean Frédéric Colombel
Journal:  Inflamm Bowel Dis       Date:  2007-09       Impact factor: 5.325

8.  Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.

Authors:  William J Sandborn; Jaroslaw Regula; Brian G Feagan; Elena Belousova; Njegica Jojic; Milan Lukas; Bruce Yacyshyn; Piotr Krzeski; Chyon-Hwa Yeh; Christi A Messer; Stephen B Hanauer
Journal:  Gastroenterology       Date:  2009-09-18       Impact factor: 22.682

9.  5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.

Authors:  L R Sutherland; F Martin; S Greer; M Robinson; N Greenberger; F Saibil; T Martin; J Sparr; E Prokipchuk; L Borgen
Journal:  Gastroenterology       Date:  1987-06       Impact factor: 22.682

10.  Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.

Authors:  S B Hanauer; W J Sandborn; C Dallaire; A Archambault; B Yacyshyn; C Yeh; N Smith-Hall
Journal:  Can J Gastroenterol       Date:  2007-12       Impact factor: 3.522
View more
  1 in total

Review 1.  Natural compounds as safe therapeutic options for ulcerative colitis.

Authors:  Mukta Gupta; Vijay Mishra; Monica Gulati; Bhupinder Kapoor; Amrinder Kaur; Reena Gupta; Murtaza M Tambuwala
Journal:  Inflammopharmacology       Date:  2022-02-25       Impact factor: 4.473
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.